Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SBT 101

Next Previous
Drug Profile

SBT 101

Alternative Names: AAV9-ABCD1; AAV9-hABCD1; SBT-101 - SwanBio Therapeutics; SBT101

Latest Information Update: 10 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SwanBio Therapeutics
  • Class Adrenoleucodystrophy gene therapies; Gene therapies
  • Mechanism of Action ALDP expression stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenomyeloneuropathy
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Adrenomyeloneuropathy

Most Recent Events

  • 31 Oct 2025 Discontinued - Phase-I/II for Adrenomyeloneuropathy (In the elderly, In adults) in Netherlands, USA (Intrathecal) (NCT05394064) (CTIS-2021-004410-19)
  • 31 Aug 2025 SwanBio Therapeutics terminates the phase I/II PROPEL trial in adrenomyeloneuropathy in the US and Netherlands (Intrathecal) due to strategic reasons(NCT05394064)
  • 16 May 2025 Updated adverse events data from a I/II PROPEL trial in adrenomyeloneuropathy released by Spur Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top